Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTUITT-NF2: Targeted Therapies in NF2-Related Schwannomatosis
NCT04374305Phase 2Recruiting
- Start
- Jun 2020
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of brigatinib, neratinib, retifanlimab, bevacizumab in neurofibromatosis type 2 (NF2), vestibular schwannoma (VS), schwannoma, meningioma, ependymoma. Started Jun 2020; status: recruiting.
02
Drugs
brigatinibneratinibretifanlimabbevacizumab
03
Conditions
neurofibromatosis type 2 (NF2)vestibular schwannoma (VS)schwannomameningiomaependymoma
Beyond the preview
Go deeper on NCT04374305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04374305.